Calidi Biotherapeutics, Inc. announced the closing of its public offering, raising $6.9 million in gross proceeds. The offering included common stock units and pre-funded warrant units, with a price per unit of $2.00 and $1.999 respectively. The securities were offered through a registration statement on Form S-1. Calidi Biotherapeutics is a clinical-stage biotechnology company developing targeted therapies for genetic medicines. The company’s Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery to metastatic sites. Calidi is also developing protected virotherapies for injectable cancer indications. For more information, visit www.calidibio.com.

Read more at GlobeNewswire: Calidi Biotherapeutics Announces Closing of $6.9 Million